Germany's Bayer plans to invest $2.2-bn in a new pharmaceutical manufacturing site in New Albany, Ohio, the US. The company said the project builds on more than $7-bn spent on pharma R&D and manufacturing in the US over the past five years.
The project is a central element of Bayer's long-term growth strategy in the US, its largest pharmaceuticals market. "Bayer has long seen the United States as a key manufacturing base and innovation hub," said Mr. Bill Anderson, CEO of Bayer. The site will serve patients in the US as well as globally.
Mr. Sebastian Guth, global Chief Operating Officer of Bayer Pharmaceuticals and President of Bayer US, said the expansion will help meet demand from customers and patients in the US, which he described as the company's fastest-growing pharmaceuticals market.
The flexible, modular campus is designed to combine drug substance and drug product manufacturing and to use advanced digital and automation technologies. It will initially support Bayer's portfolio in oncology, cardiovascular and renal care. The first module, dedicated to drug substance manufacturing, is expected to become operational in 2031, with a second module for drug product manufacturing planned for 2034.
The site will complement Bayer's US pharmaceuticals headquarters in Whippany, New Jersey, and its other sites in Pittsburgh, Pennsylvania; Berkeley, California; Cambridge, Massachusetts; Research Triangle Park, North Carolina; and San Diego, California.
"Our planned presence in Ohio will further enhance our ability to serve our markets with greater resilience and reliability," said Mr. Holger Weintritt, head of product supply at Bayer's pharmaceuticals division.
The site will also form part of a new US-based collaboration ecosystem, which aims to connect academic innovation with advanced manufacturing expertise to support future pharmaceutical production, the company said.


6 October, 2026 17:06:07 IST 
















